Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to -$890,536.

  • Cumberland Pharmaceuticals' Net Cash Flow fell 794.06% to -$890,536 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 117.41%. This contributed to the annual value of -$357,440 for FY2024, which is 75.11% up from last year.
  • Cumberland Pharmaceuticals' Net Cash Flow amounted to -$890,536 in Q3 2025, which was down 190.98% from $978,868 recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Net Cash Flow peaked at $1.9 million during Q2 2023, and registered a low of -$9.8 million during Q1 2022.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Net Cash Flow value was $128,308 (recorded in 2024), while the average stood at -$414,657.
  • Data for Cumberland Pharmaceuticals' Net Cash Flow shows a peak YoY increase of 666.90% (in 2022) and a maximum YoY decrease of 5,879.04% (in 2022) over the last 5 years.
  • Over the past 5 years, Cumberland Pharmaceuticals' Net Cash Flow (Quarterly) stood at $1.2 million in 2021, then tumbled by 81.93% to $216,432 in 2022, then slumped by 186.10% to -$186,341 in 2023, then skyrocketed by 368.02% to $499,430 in 2024, then plummeted by 794.06% to -$890,536 in 2025.
  • Its last three reported values are -$890,536 in Q3 2025, $978,868 for Q2 2025, and -$2.9 million during Q1 2025.